An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease
Background: Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and the fusion (F) protein is a target for neutralizing antibodies and vaccine development. This study aimed to investigate the immunogenicity and efficacy of an mRNA-base...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/52 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587389244014592 |
|---|---|
| author | Jianglong Li Haiyan Long Shaoyi Chen Zhendong Zhang Shuang Li Qi Liu Jun Liu Jiaru Cai Liping Luo Yucai Peng |
| author_facet | Jianglong Li Haiyan Long Shaoyi Chen Zhendong Zhang Shuang Li Qi Liu Jun Liu Jiaru Cai Liping Luo Yucai Peng |
| author_sort | Jianglong Li |
| collection | DOAJ |
| description | Background: Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and the fusion (F) protein is a target for neutralizing antibodies and vaccine development. This study aimed to investigate the immunogenicity and efficacy of an mRNA-based RSV vaccine with an F protein sequence. Methods: We designed an mRNA construct encoding a modified RSV F protein, which was further developed into an LNP-encapsulated mRNA vaccine (LVRNA007). LVRNA007 was administered to mice and cotton rats, followed by immunogenicity analysis and viral challenge studies. Protection of rodents from the viral infection was evaluated based on the presence of the virus in the lung and pathological examination of respiratory tissues. Results: LVRNA007 induced robust humoral and cellular immune responses in both mice and cotton rats, with neutralization antibody levels in the immunized animals maintained at high levels for over one year. Vaccination of LVRNA007 also protected the rodents from RSV challenge, judged by the much decreased virus titer and the pathological score in the lung tissue. In addition, no vaccine-enhanced disease (VED) phenomenon was observed with LVRNA007 vaccination. Conclusions: Based on the preclinical immunogenicity and efficacy data, LVRNA007 could be a potential promising vaccine for prophylaxis of RSV infection. |
| format | Article |
| id | doaj-art-d099db11754a4cbdab92520222096c70 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-d099db11754a4cbdab92520222096c702025-01-24T13:51:47ZengMDPI AGVaccines2076-393X2025-01-011315210.3390/vaccines13010052An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory DiseaseJianglong Li0Haiyan Long1Shaoyi Chen2Zhendong Zhang3Shuang Li4Qi Liu5Jun Liu6Jiaru Cai7Liping Luo8Yucai Peng9Liverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaLiverna Therapeutics Inc., Zhuhai 519000, ChinaBackground: Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and the fusion (F) protein is a target for neutralizing antibodies and vaccine development. This study aimed to investigate the immunogenicity and efficacy of an mRNA-based RSV vaccine with an F protein sequence. Methods: We designed an mRNA construct encoding a modified RSV F protein, which was further developed into an LNP-encapsulated mRNA vaccine (LVRNA007). LVRNA007 was administered to mice and cotton rats, followed by immunogenicity analysis and viral challenge studies. Protection of rodents from the viral infection was evaluated based on the presence of the virus in the lung and pathological examination of respiratory tissues. Results: LVRNA007 induced robust humoral and cellular immune responses in both mice and cotton rats, with neutralization antibody levels in the immunized animals maintained at high levels for over one year. Vaccination of LVRNA007 also protected the rodents from RSV challenge, judged by the much decreased virus titer and the pathological score in the lung tissue. In addition, no vaccine-enhanced disease (VED) phenomenon was observed with LVRNA007 vaccination. Conclusions: Based on the preclinical immunogenicity and efficacy data, LVRNA007 could be a potential promising vaccine for prophylaxis of RSV infection.https://www.mdpi.com/2076-393X/13/1/52RSVmRNA vaccineF proteinLVRNA007viral challenge study |
| spellingShingle | Jianglong Li Haiyan Long Shaoyi Chen Zhendong Zhang Shuang Li Qi Liu Jun Liu Jiaru Cai Liping Luo Yucai Peng An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease Vaccines RSV mRNA vaccine F protein LVRNA007 viral challenge study |
| title | An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease |
| title_full | An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease |
| title_fullStr | An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease |
| title_full_unstemmed | An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease |
| title_short | An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease |
| title_sort | mrna based respiratory syncytial virus vaccine elicits strong neutralizing antibody responses and protects rodents without vaccine associated enhanced respiratory disease |
| topic | RSV mRNA vaccine F protein LVRNA007 viral challenge study |
| url | https://www.mdpi.com/2076-393X/13/1/52 |
| work_keys_str_mv | AT jianglongli anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT haiyanlong anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT shaoyichen anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT zhendongzhang anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT shuangli anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT qiliu anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT junliu anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT jiarucai anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT lipingluo anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT yucaipeng anmrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT jianglongli mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT haiyanlong mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT shaoyichen mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT zhendongzhang mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT shuangli mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT qiliu mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT junliu mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT jiarucai mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT lipingluo mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease AT yucaipeng mrnabasedrespiratorysyncytialvirusvaccineelicitsstrongneutralizingantibodyresponsesandprotectsrodentswithoutvaccineassociatedenhancedrespiratorydisease |